- Home
- SSM vs SILO Comparison
SSM vs SILO Comparison
Compare SSM & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSM
- SILO
- Stock Information
- Founded
- SSM N/A
- SILO 2010
- Country
- SSM Germany
- SILO United States
- Employees
- SSM 43
- SILO N/A
- Industry
- SSM
- SILO Apparel
- Sector
- SSM
- SILO Consumer Discretionary
- Exchange
- SSM Nasdaq
- SILO Nasdaq
- Market Cap
- SSM 9.9M
- SILO 8.0M
- IPO Year
- SSM N/A
- SILO N/A
- Fundamental
- Price
- SSM $6.64
- SILO $0.43
- Analyst Decision
- SSM
- SILO
- Analyst Count
- SSM 0
- SILO 0
- Target Price
- SSM N/A
- SILO N/A
- AVG Volume (30 Days)
- SSM N/A
- SILO 275.0K
- Earning Date
- SSM N/A
- SILO 11-13-2025
- Dividend Yield
- SSM N/A
- SILO N/A
- EPS Growth
- SSM N/A
- SILO N/A
- EPS
- SSM N/A
- SILO N/A
- Revenue
- SSM N/A
- SILO $72,102.00
- Revenue This Year
- SSM N/A
- SILO $1.86
- Revenue Next Year
- SSM N/A
- SILO N/A
- P/E Ratio
- SSM N/A
- SILO N/A
- Revenue Growth
- SSM N/A
- SILO N/A
- 52 Week Low
- SSM N/A
- SILO $0.36
- 52 Week High
- SSM N/A
- SILO $3.37
- Technical
- Relative Strength Index (RSI)
- SSM N/A
- SILO 38.57
- Support Level
- SSM N/A
- SILO $0.39
- Resistance Level
- SSM N/A
- SILO $0.43
- Average True Range (ATR)
- SSM 0.00
- SILO 0.04
- MACD
- SSM 0.00
- SILO -0.00
- Stochastic Oscillator
- SSM 0.00
- SILO 39.29
About SSM Sono Group N.V. Ordinary Shares
Sono Group NV is engaged in the field of solar-powered electric mobility. With its proprietary solar technology, the company is able to integrate solar panels into a vehicle's bodywork, using energy captured from the sun to charge the vehicle's battery. The group is engaged in the design and development of its own first solar electric vehicle, the Sion. Its Products and Services includes Complete Solar Solutions, Solar Charge Controllers, Solar Modules, and Data Services and Engineering Services.
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.